MiR-23b targets proline oxidase, a novel tumor suppressor protein in renal cancer

Oncogene

Volumn 29, Issue 35, 2010, Pages 4914-4924

  Liu, W ^a   Zabirnyk, O ^a   Wang, H ^a   Shiao, Y H ^a   Nickerson, M L ^a   Khalil, S ^a   Anderson, L M ^a   Perantoni, A O ^a   Phang, J M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

miR 23b; proline oxidase; renal cancer; ROS; tumor suppressor

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; MESSENGER RNA; MICRORNA; MIR 23B; PROLINE DEHYDROGENASE; REACTIVE OXYGEN METABOLITE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MIRN23 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; UPREGULATION; CELL PROLIFERATION; DOWN REGULATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; KIDNEY TUMOR; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MICRORNAS; PROLINE OXIDASE; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 77956342208     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.237     Document Type: Article

References (43)

1. Bartel DP. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
2. Chen K, Rajewsky N. (2007). The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet 8: 93-103.
3. Chow TF YY, Lianidou E, Romaschin AD, Honey RJ, Stewart R, Pace KT et al. (2009). Differential expression profiling of micro-RNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem 43: 150-158.
4. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. (2004). Processing of primary microRNAs by the microprocessor complex. Nature 432: 231-235.
5. Donald SP, Sun XY, Hu CA, Yu J, Mei JM, Valle D et al. (2001). Proline oxidase, encoded by p53-induced gene-6, catalyzes the generation of proline-dependent reactive oxygen species. Cancer Res 61: 1810-1815.
6. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M et al. (2009). miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 69: 2287-2295.
7. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T et al. (2009). c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458: 762-765.
8. Girgin C, Tarhan H, Hekimgil M, Sezer A, Gurel G. (2001). P53 mutations and other prognostic factors of renal cell carcinoma. Urol Int 66: 78-83.
9. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P et al. (2007). Micro-RNA profiling in kidney and bladder cancers. UrolOncol 25: 387-392.
10. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N et al. (2004). The microprocessor complex mediates the genesis of microRNAs. Nature 432: 235-240.
11. Guimbellot JS, Erickson SW, Mehta T, Wen H, Page GP, Sorscher EJ et al. (2009). Correlation of microRNA levels during hypoxia with predicted target mRNAs through genome-wide microarray analysis. BMC Med Genomics 2: 15.
12. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070.
13. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A et al. (2005). RAS is regulated by the let-7 microRNA family. Cell 120: 635-647.
14. Kaelin Jr WG. (2009). Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer 115: 2262-2272.
15. Kim S, Lee UJ, Kim MN, Lee EJ, Kim JY, Lee MY et al. (2008). MicroRNA miR-199a regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J Biol Chem 283: 18158-18166.
16. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin Jr WG. (2002). Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1: 237-246.
17. Kulshreshtha R, Davuluri RV, Calin GA, Ivan M. (2008). A microRNA component of the hypoxic response. Cell Death Differ 15: 667-671.
18. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ et al. (2007). A microRNA signature of hypoxia. Mol Cell Biol 27: 1859-1867.
19. Lewis BP, Burge CB, Bartel DP. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
20. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J et al. (2005). Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 433: 769-773.
21. Liu Y, Borchert GL, Donald SP, Diwan BA, Anver M, Phang JM. (2009). Proline oxidase functions as a mitochondrial tumor suppressor in human cancers. Cancer Res 69: 6414-6422.
22. Liu Y, Borchert GL, Donald SP, Surazynski A, Hu CA, Weydert CJ et al. (2005). MnSOD inhibits proline oxidase-induced apoptosis in colorectal cancer cells. Carcinogenesis 26: 1335-1342.
23. Liu Y, Borchert GL, Surazynski A, Hu CA, Phang JM. (2006). Proline oxidase activates both intrinsic and extrinsic pathways for apoptosis: the role of ROS/superoxides, NFAT and MEK/ERK signaling. Oncogene 25: 5640-5647.
24. Liu Y, Borchert GL, Surazynski A, Phang JM. (2008). Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers. Oncogene 27: 6729-6737.
25. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H et al. (2008). Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7: 2591-2600.
26. Ma L, Teruya-Feldstein J, Weinberg RA. (2007). Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449: 682-688.
27. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. (2002). The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1: 247-255.
28. Maxwell SA, Rivera A. (2003). Proline oxidase induces apoptosis in tumor cells, and its expression is frequently absent or reduced in renal carcinomas. J Biol Chem 278: 9784-9789.
29. Migliore C, Petrelli A, Ghiso E, Corso S, Capparuccia L, Eramo A et al. (2008). MicroRNAs impair MET-mediated invasive growth. Cancer Res 68: 10128-10136.
30. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM et al. (2006). A pattern-based method for the identification of microRNA binding sites and their corresponding heteroduplexes. Cell 126: 1203-1217.
31. Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T et al. (2008). Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J Pathol 216: 418-427.
32. Nass D, Rosenwald S, Meiri E, Gilad S, Tabibian-Keissar H, Schlosberg A et al. (2009). MiR-92b and miR-9/9 are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol 19: 375-383.
33. Northcott PA, Fernandez LA, Hagan JP, Ellison DW, Grajkowska W, Gillespie Y et al. (2009). The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res 69: 3249-3255.
34. Pandhare J, Cooper SK, Phang JM. (2006). Proline oxidase, a proapoptotic gene, is induced by troglitazone: evidence for both peroxisome proliferator-activated receptor gamma-dependent and -independent mechanisms. J Biol Chem 281: 2044-2052.
35. Phang JM. (1985). The regulatory functions of proline and pyrroline-5-carboxylic acid. Curr Top Cell Regul 25: 91-132.
36. Phang JM, Pandhare J, Liu Y. (2008). The metabolism of proline as microenvironmental stress substrate. J Nutr 138: 2008S-2015S.
37. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. (1997). A model for p53-induced apoptosis. Nature 389: 300-305.
38. Smaldone MC, Maranchie JK. (2009). Clinical implications of hypoxia inducible factor in renal cell carcinoma. Urol Oncol 27: 238-245.
39. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL. (2003). Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res 63: 6130-6134.
40. Suzuki Y, Tamura G, Satodate R, Fujioka T. (1992). Infrequent mutation of p53 gene in human renal cell carcinoma detected by polymerase chain reaction single-strand conformation polymorphism analysis. Jpn J Cancer Res 83: 233-235.
41. Williams AE. (2008). Functional aspects of animal microRNAs. Cell Mol Life Sci 65: 545-562.
42. Yang H, Kong W, He L, Zhao JJ, ODonnell JD, Wang J et al. (2008). MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68: 425-433.
43. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI et al. (2007). HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11: 407-420.